Business Impact
- Validation timeline overruns delaying SAP EWM go-live
- IQ / OQ / PQ execution cycles consuming months of resource time
- Rising consultant costs due to manual documentation overhead
- Regulatory compliance gaps under pharmaceutical industry standards increasing audit risk
- URS and Functional Specification sign-off cycles causing project bottlenecks
- Validation Master Plan milestones missed repeatedly
- QA team bandwidth exhausted on repetitive manual test documentation
The Challenge
Woburn, Massachusetts. A mid-sized pharmaceutical manufacturer — producing serialised, regulated medicines for distribution across the United States and Europe.
They had invested heavily in SAP EWM. The system was capable, configured and ready. The warehouse team was trained. Leadership had signed off on the go-live roadmap.
Then the GxP validation cycle began.
And everything slowed down.
The QA team was buried in documentation. Every IQ, OQ and PQ protocol needed to be written from scratch, reviewed, approved, executed and then documented all over again. The Validation Master Plan had milestones that kept moving forward on paper — but never seemed to get closer in reality.
Three months into the CSV process, the project manager pulled up the tracker in a Monday morning meeting and said nothing for a moment. Then —
“We are four months behind and we have not even started OQ execution.”
Nobody in that room had a good answer.
What was actually happening across the organisation during those months —
- Over $60,000 monthly (as reported by the client) in external validation consultant fees — specialists brought in to write protocols, review documents and manage test execution that had no end in sight
- Go-live date slipped three times — from Q2 to Q3 to Q4 — each slip carrying its own cascade of rescheduled training, delayed warehouse transitions and renegotiated vendor contracts
- QA team logging 60 to 70 hour weeks — not doing quality work, but chasing document approvals, version control issues and manual test scripts that needed constant updating every time a configuration changed
- Regulatory audit readiness was deteriorating — electronic record keeping and approval workflows were not consistently maintained across the full validation lifecycle, creating exposure under pharmaceutical computerised system regulations governing data integrity and electronic records
- URS sign-off cycles were taking three to four weeks per iteration — every change request triggering a full review loop that consumed everyone’s calendar
- The compliance director had stopped giving go-live estimates to senior leadership entirely — she simply did not have a number she could stand behind
This was not a technology failure. The SAP EWM system was working perfectly.
The bottleneck was the validation process itself — slow, manual, repetitive and completely disconnected from the pace the business needed to move at.
The Call to SCM Champs
By month five, the VP of Operations had seen enough.
A colleague in the industry — a supply chain director at another Massachusetts pharma firm — mentioned SCM Champs in passing. Not as a formal recommendation. Just a quiet word over coffee —
“They brought pre-built validation packages for our EWM go-live. Our CSV timeline improved significantly. You should call them.”
The Woburn team had been at it for five months with no end in sight.
The VP sent an email to SCM Champs that same evening. The reply came the next morning. A scoping call was set for the following day — no lengthy intake forms, no generic capability decks. Just a direct conversation with people who had clearly done this before.
What SCM Champs Actually Found
When the SCM Champs validation team reviewed the project, the picture became clear very quickly. And honestly — what they found was not unusual. They had seen it in almost every manual GxP validation engagement across the industry.
Finding 1 — Everything was being built from scratch
There were no pre-built validation templates in place. Every IQ, OQ and PQ protocol was being written from zero — by consultants billing by the hour. Every test script was manually authored for this specific project. Nothing was reusable. Nothing was standardised. Every document looked different from the last.
Finding 2 — No traceability matrix was maintained in real time
The Requirements Traceability Matrix — connecting URS requirements through Functional Specifications, Design Specifications and live test evidence — was being updated manually in spreadsheets after the fact. When configurations changed, the traceability matrix was often weeks behind. This was opening serious gaps in the documentation trail — creating direct exposure under pharmaceutical computerised system regulations governing data integrity and electronic records.
Finding 3 — Validation phases were running sequentially with no risk-based planning
Every validation phase was waiting for the previous one to fully close before the next one began — without any formal risk assessment to determine where controlled overlap could be safely applied. IQ completion was waiting on final sign-offs. OQ could not start until IQ was formally approved. PQ was not even being scoped until OQ was done. In a project of this size, this approach was adding months of pure waiting time to the timeline.
Finding 4 — Test management was fragmented across spreadsheets and emails
The team was managing test execution through shared spreadsheets and email chains. SAP Solution Manager — which supports structured test management, documentation tracking and sign-off workflows directly within the SAP landscape — was available but completely unused. Every test result was being manually transcribed. Every defect was being tracked in a separate log. The audit trail was fragmented across multiple tools and inboxes.
Finding 5 — Change control was triggering full re-validation loops unnecessarily
Every minor configuration change — even low-risk adjustments — was being routed through a full change control and re-validation cycle. There was no risk-based framework applied to determine which changes genuinely required re-testing and which could be resolved with a documented impact assessment. This alone was responsible for significant delay across the project timeline.
What SCM Champs Delivered — Step by Step
Step 1 — Deployed Pre-Built GxP Validation Package for SAP EWM
SCM Champs arrived with a complete library of ready-to-use, pharma-grade validation documentation — purpose built for SAP EWM environments operating under GxP requirements. This included —
- A fully structured Validation Master Plan built around the specific regulatory expectations pharmaceutical manufacturers face during computerised system validation
- Ready-to-execute IQ, OQ and PQ protocols covering the full scope of SAP EWM warehouse processes — structured around their correct purpose:
- IQ — Installation Qualification confirmed that SAP EWM was installed and configured correctly against vendor specifications — infrastructure, system settings, interfaces and environment
- OQ — Operational Qualification verified that each system function performed correctly in the operational environment — tested against URS and Functional Specification requirements across all core EWM processes including Goods Receipt, Putaway strategies, Stock Transfers, Pick and Pack, Goods Issue, Batch and Serial number management, Handling Unit management and SAP ERP to EWM integration
- PQ — Performance Qualification validated that the end-to-end business processes performed consistently and correctly under realistic operating conditions — covering full warehouse cycles, QM integration, exception handling and cross-system posting behaviour
- URS and Functional Specification templates mapped directly to SAP EWM standard functionality — reviewed, structured and ready for client sign-off
- A live Requirements Traceability Matrix maintained throughout the entire engagement — every requirement linked to its corresponding test evidence from day one
What previously consumed weeks of consultant authoring time became a focused configuration and review exercise. Manual effort was significantly reduced from day one.
Step 2 — Applied Risk-Based Validation Strategy Aligned to GAMP 5
Not every process in SAP EWM carries the same compliance weight. SCM Champs applied a structured risk-based validation strategy grounded in GAMP 5 guidelines — formally categorising each system function by its impact on product quality, patient safety and data integrity.
SAP EWM as a configured commercial off-the-shelf system falls under GAMP 5 Software Category 4 — requiring a validation approach proportionate to the configuration complexity and business risk of each process area. Processes at the highest risk level — serialisation, batch management, goods issue to production, QM integration — received complete IQ OQ PQ coverage with full documentation. Lower-risk administrative and reporting functions were handled through documented risk assessments rather than full test cycles.
This risk-based approach is not a shortcut — it is the correct methodology. It removed weeks of unnecessary execution from the project timeline without any compromise to compliance standing.
Step 3 — Structured Test Management via SAP Solution Manager
SAP Solution Manager was configured as the central test management platform for the validation programme — providing structured test case management, documentation tracking and defect resolution workflows directly within the SAP landscape. Test cases were loaded, assigned and executed within Solution Manager. Defects were raised, tracked and resolved in the same environment — creating a consistent, traceable electronic record across the validation lifecycle.
It is worth noting that SAP Solution Manager is one strong option for validation test management in SAP environments. Depending on client infrastructure and preference, alternative platforms such as HP ALM or structured document-based approaches may also be used effectively — what matters is that the chosen tool maintains a complete, auditable trail from test execution through to sign-off.
Step 4 — Introduced Controlled Phase Overlap Based on Risk Assessment
IQ, OQ and PQ are sequential validation phases by design — each serving a distinct and specific purpose in the validation lifecycle. Compressing or merging these phases without formal justification would be a compliance risk, not an efficiency gain.
What SCM Champs introduced was a formally documented controlled overlap approach — applied only where the risk assessment specifically supported it. Where IQ sign-off on one process area was complete and approved, OQ scripting and preparation for that area began in parallel with IQ execution on remaining areas. PQ scoping commenced once sufficient OQ evidence was available to support it.
Every overlap decision was documented, risk-justified and approved. Nothing was rushed. The result was a meaningful reduction in overall timeline without a single compromise to validation integrity.
Step 5 — Established Risk-Based Change Control Process
A structured change impact assessment process was introduced — built around the client’s existing change control procedures. Every configuration change was now evaluated against a defined risk framework before any re-validation activity was triggered.
Low and medium risk changes — those with no direct impact on validated GxP functions — were resolved through documented impact assessments. Only changes directly affecting high-risk process areas required formal re-testing with updated test evidence. The cycle of disproportionate re-validation that had been consuming weeks of project time was brought under control.
Step 6 — Full Validation Lifecycle Review and Regulatory Readiness Assessment
Before closing the validation lifecycle, SCM Champs completed a thorough end-to-end review of all validation deliverables — checking every document against the regulatory expectations pharmaceutical manufacturers face during inspections and internal audits —
- Electronic records completeness and accuracy across all validated system functions
- Audit trail integrity maintained throughout the full validation lifecycle
- Digital approval workflows confirmed across all sign-off points
- Traceability matrix verified from URS through to final test evidence — no gaps
- Validation Summary Report authored, reviewed and approved
The client’s compliance team completed their internal review of the full validation package. Audit readiness was confirmed and the team proceeded to go-live with confidence.
What Changed — Business Impact After Delivery
The difference was visible from the first weeks of the engagement.
- CSV timeline improvement of approximately 40% (as reported by the client) compared to the original projected duration
- External consultant costs reduced significantly (as reported by the client) — ready-to-use templates removed the bulk of manual authoring hours from the project
- Go-live achieved in Q4 as originally planned — the third rescheduled date finally held
- Regulatory audit readiness strengthened — the full validation package was inspection-ready at go-live with no open documentation gaps
- QA team manual effort reduced substantially — the unsustainable workload that had built up over months began easing within the first three weeks of the engagement
- Full Requirements Traceability Matrix delivered — clean, complete and traceable from URS through to final test evidence
- The compliance director finally had a position she could take to senior leadership with confidence
The VP of Operations sent a short note to the SCM Champs team on go-live day —
“Five months of going nowhere. Working with your team changed that. I wish we had made this call sooner.”
That note still sits in the SCM Champs project archive.
Why SCM Champs
GxP validation is not where SAP projects should slow down. It is where they should accelerate — because the system is ready, the business is ready, and the only thing standing between the team and go-live is documentation, testing and compliance evidence.
SCM Champs reduces that gap meaningfully.
With a ready-to-deploy validation programme designed specifically for SAP EWM in GxP pharmaceutical environments — structured around the regulatory frameworks that North American and European pharma manufacturers operate within — the team brings structure, speed and compliance confidence to every engagement.
Across North America and Europe, SCM Champs has supported pharmaceutical manufacturers, distributors and 3PLs in closing their CSV timelines more efficiently, with greater documentation quality and stronger regulatory readiness at go-live.
If your validation cycle is running over, your go-live is slipping and your QA team is carrying a workload that has no end in sight —
You do not need more consultants writing documents. You need SCM Champs.